You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(01875.HK)成立合營企業華曜醫藥(蘇州)

格隆匯11月23日丨東曜藥業-B(01875.HK)公告,於2021年11月23日,曜展(爲公司全資附屬公司)、華潤醫藥商貿(爲獨立第三方)及蘇州華曜員(爲員工持股平臺)共同成立合營企業公司華曜醫藥(蘇州)有限公司。

華曜的註冊資本總額爲人民幣5,000萬元。曜展、華潤醫藥商貿及蘇州華曜員分別出資人民幣2,350萬元(相當於註冊資本的47%)、人民幣1,700萬元(相當於註冊資本的34%)及人民幣950萬元(相當於註冊資本的19%)。

公司表示,因應國家醫藥政策改革及發展趨勢,集團擬協同華潤醫藥商貿(作爲策略聯盟夥伴)積極推行腫瘤藥物商業運營模式變革及腫瘤藥物市場的創新發展。華曜爲一間醫藥銷售公司,擬主要從事推廣及銷售創新腫瘤藥物以及向癌症患者及腫瘤醫療專業人士提供專業醫學服務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account